Always consult a qualified healthcare provider about your specific situation
This custom program combines several treatments to help you get the best results
Finally, in obese diabetic individuals, the GLP-1R/GIPR/GcgR tri-agonist may be the most appropriate option, having the greatest potential to improve metabolism by weight-dependent and -independent mechanisms
Regular follow-up appointments, typically scheduled every 4 to 12 weeks during the initial treatment phase, allow for dose adjustments, side effect management, and monitoring of therapeutic outcomes
Upcoming 2026 readouts TRIUMPH-1: the pivotal general obesity study TRIUMPH-1 is the trial that will anchor the weight-management NDA
Advances in Nutrition , 12(6), 25402552